Insmed (INSM) Capital Expenditures Growth (1y) (2012 - 2026)
Insmed (INSM) Capital Expenditures Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | - |
| 10 | Insmed | 23.05 Bn | 21.83 Bn | 258.54 Mn | -65.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.44% |
| Dec 31, 2025 | 534.94% |
| Sep 30, 2025 | -330.47% |
| Jun 30, 2025 | 122.67% |
| Mar 31, 2025 | 3,124.02% |
| Dec 31, 2024 | -225.87% |
| Sep 30, 2024 | 173.97% |
| Jun 30, 2024 | -478.47% |
| Mar 31, 2024 | -109.80% |
| Dec 31, 2023 | 168.46% |
| Sep 30, 2023 | -56.32% |
| Jun 30, 2023 | 39.81% |
| Mar 31, 2023 | 99.76% |
| Dec 31, 2022 | -117.20% |
| Sep 30, 2022 | 468.40% |
| Jun 30, 2022 | 119.28% |
| Mar 31, 2022 | -91.38% |
| Dec 31, 2021 | 1,157.77% |
| Sep 30, 2021 | -3.52% |
| Jun 30, 2021 | -995.13% |